Compare ACADIA Pharmaceuticals Inc. (ACAD) vs Teucrium Soybean Fund (SOYB) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
ACADIA Pharmaceuticals Inc. vs Teucrium Soybean Fund — how do they compare? ACADIA Pharmaceuticals Inc. trades at $25.78 (market cap $4.49B), while Teucrium Soybean Fund trades at $25.38. The key difference: Teucrium Soybean Fund is trading nearer its 52-week high, ACADIA Pharmaceuticals Inc. nearer its low. Which is the better fit depends on your goals.
| ACAD | SOYB | |
|---|---|---|
Market Cap | $4.49B | — |
Sector | Health | Commodities - Metals/Agriculture |
52-Week High | $28.06 | $25.36 |
52-Week Low | $20.06 | $21.07 |
Enterprise Value | $3.69B | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ACAD trades at $26.20, up 0.89% today, with strong analyst consensus (70% buy ratings) and a $33.67 price target. Recent CHMP recommendation for Daybue in Europe (Business Wire, June 26, 2026) drove positive sentiment. The stock shows bullish technical signals with moving averages supporting upside, though RSI levels indicate overbought conditions. Fundamentally, revenue grew to $1.07B in 2025 with a robust net income margin of 34.3%, though Q1 2026 earnings missed expectations.
Outlook remains positive given commercial execution and pipeline catalysts like remlifanserin data, but risks include earnings volatility and regulatory dependencies. The stock offers growth potential in neuropsychiatry markets, balanced by execution risks in clinical trials and competitive pressures.
SOYB trades at $25.24, up 3.27% today, with a bullish technical signal from moving averages and a neutral stance from oscillators. Key support sits at $24 and resistance at $25. Recent news highlights potential tailwinds from China's $17 billion U.S. crop purchase pledge through 2028, which may benefit agricultural sectors including soybeans.
The stock's outlook is supported by positive technical momentum and favorable sector news, but investment appeal is tempered by a lack of available fundamental data on profitability and valuation. Risks include dependence on agricultural commodity cycles and trade policy stability. Investors should seek updated financials for a complete assessment.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About ACADIA Pharmaceuticals Inc.
Acadia Pharmaceuticals is a biotechnology company that develops and commercializes biopharmaceutical products to address central nervous system disorders. The company aims to discover small molecule drugs that address disorders such as Parkinson's, Alzheimer's, and schizophrenia. Acadia also seeks to in-license or acquire complementary products and candidates. The company's patent applications claim proprietary technology, including novel methods of screening and chemical synthetic methods, novel drug targets, and novel compounds identified using its technology.
Read more on ACAD →About Teucrium Soybean Fund
SOYB is a commodity ETF that provides exposure to the price of soybean futures. It utilizes a laddered strategy by investing in several benchmark futures contracts to reduce the impact of roll costs and contango in the agricultural market.
Read more on SOYB →
